ArticleScience immunology2023
Preexisting tumor-resident T cells with cytotoxic potential associate with response to neoadjuvant anti-PD-1 in head and neck cancer.
Registry-linked trialOpen access · greenAbstract read
In one paragraph
Article in Science immunology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT02296684 (Immunotherapy With MK-3475 in Locoregionally Advanced, Surgically Resectable Head and Neck Squamous Cell Carcinoma), which is not on this map. Cited by 80 papers, 2 of them syntheses that pooled it.
0numbers the graph read from it
0cells of the map it votes in
80citing papers in PubMed, 2 pooled it
24.6field-weighted citation impact, top 1% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Immunotherapy With MK-3475 in Locoregionally Advanced, Surgically Resectable Head and Neck Squamous Cell Carcinoma
Who cites it
80 citing papers in PubMed, 2 syntheses or guidelines pooled it, 107 citations in OpenAlex.
- Single-cell meta-analysis of T cells reveals clonal dynamics of response to checkpoint immunotherapy.Cell genomics · 2025Pooled it
- Tissue-resident memory T-cell expressions and their prognostic role in head and neck squamous cell carcinoma: a systematic review and meta-analysis.BMC cancer · 2025Pooled it
- Pre-existing systemic immune state and dynamic myeloid remodeling shape response to neoadjuvant PD-L1 blockade.Journal for immunotherapy of cancer · 2026Trial
- Mirvetuximab soravtansine plus pembrolizumab in recurrent folate receptor alpha-positive uterine serous carcinoma: a phase II trial.Nature communications · 2026Trial
- 4-1BBCell reports. Medicine · 2025Trial
- Depletion of Effector Regulatory T Cells Associates with Major Response to Induction Dual Immune Checkpoint Blockade.Cancer discovery · 2025Trial
- Distinct CD8Cancer cell · 2025Trial
- Response-Adaptive Surgical Timing in Neoadjuvant Immunotherapy Demonstrates Enhanced Pathologic Treatment Response in Head and Neck Squamous Cell Carcinoma.Clinical cancer research : an official journal of the American Association for Cancer Research · 2025Trial
- Characterization of persistent HPV-specific activated T cells in head and neck squamous cell carcinoma.Oncoimmunology · 2026Article
- Optimizing immunotherapy for head and neck squamous cell carcinoma: recent advances and future directions.Annals of medicine · 2026Review
- Personalized neoantigen-targeting cancer vaccines in ovarian cancer: a phase 1 trial.Nature medicine · 2026Article
- Article
- CD8MedComm · 2026Review
- High-avidity TCR signaling induces a distinct KLR-positive exhaustion state in human tumor-infiltrating CD8 T cells associated with immunotherapy response.bioRxiv : the preprint server for biology · 2026Article
- β-Adrenergic Signaling Promotes Anti-Tumor Immunity in TP53-mutant Oral Squamous Cell Carcinoma.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Article
- Preexisting TCR Clones Drive Major Pathologic Responses in Patients with HNSCC Treated with Dual Immune Checkpoint Inhibitors.Clinical cancer research : an official journal of the American Association for Cancer Research · 2026Article
- scRNA-Seq reveals anti-lymphoma immune responses in mogamulizumab-associated skin eruptions.Journal of the European Academy of Dermatology and Venereology : JEADV · 2026Article
- Single-cell analysis highlights the significance of malignant cell IFN/MHC-II for immunotherapy response in head and neck squamous cell carcinoma.Cell reports. Medicine · 2026Article
- GZMK expression within activated intratumoral T-cell subsets reflects differentiation efficiency and predicts response to cancer immunotherapy.NPJ precision oncology · 2026Article
- Precision immunotherapy for head and neck cancer: therapeutic combinations, biomarker strategies, and translational challenges.Molecular cancer · 2026Review
20 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
39 authors at 8 institutions in 2 countries.
Giacomo OliveiraDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.ORCID 0000-0001-7435-5603
Ann Marie EgloffDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.ORCID 0000-0002-1182-2793
Alexander B AfeyanDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.ORCID 0000-0003-0525-7166
Jacquelyn O WolffCenter for Immuno-Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.
Zexiang ZengDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.
Rebecca D ChernockDepartment of Pathology and Immunology, Washington University School of Medicine, St. Louis, MO, USA.ORCID 0000-0001-6253-0478
Liye ZhouDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.
Cameron MessierDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.ORCID 0000-0002-2718-6525
Patrick LizotteDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.ORCID 0000-0001-9510-0036
Kathleen L PfaffCenter for Immuno-Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.ORCID 0000-0003-3311-5384
Kari StromhaugDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.
Livius PenterDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.ORCID 0000-0002-9060-0207
Robert I HaddadDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.
Glenn J HannaDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.
Jonathan D SchoenfeldDepartment of Radiation-Oncology, Brigham and Women's Hospital, Boston, MA, USA.ORCID 0000-0002-5119-0401
Laura A GoguenDepartment of Surgery, Brigham and Women's Hospital, Boston, MA, USA.
Donald J AnninoDepartment of Surgery, Brigham and Women's Hospital, Boston, MA, USA.
Vickie JoDepartment of Pathology, Brigham and Women's Hospital, Boston, MA, USA.ORCID 0000-0003-4808-2714
Peter OppeltAlvin J. Siteman Cancer Center, Washington University School of Medicine, St. Louis, MO, USA.
Patrik PipkornDepartment of Otolaryngology, Washington University School of Medicine, St. Louis, MO, USA.ORCID 0000-0002-4118-7743
Ryan JacksonDepartment of Otolaryngology, Washington University School of Medicine, St. Louis, MO, USA.ORCID 0000-0003-4626-2324
Sidharth V PuramDepartment of Otolaryngology, Washington University School of Medicine, St. Louis, MO, USA.ORCID 0000-0003-3543-889X
Randal C PanielloDepartment of Otolaryngology, Washington University School of Medicine, St. Louis, MO, USA.
Jason T RichDepartment of Otolaryngology, Washington University School of Medicine, St. Louis, MO, USA.
Jason WebbDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.
Jose P ZevallosDepartment of Otolaryngology, University of Pittsburgh Medical Center, Pittsburgh, PA, USA.
Mena MansourDepartment of Pathology and Immunology, Washington University School of Medicine, St. Louis, MO, USA.ORCID 0000-0003-1358-1062
Jingxin FuDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.ORCID 0000-0002-4028-3661
Gavin P DunnDepartment of Neurological Surgery, Massachusetts General Hospital, Boston, MA, USA.
Scott J RodigDepartment of Medicine, Brigham and Women's Hospital, Boston, MA, USA.
Jessica LeyAlvin J. Siteman Cancer Center, Washington University School of Medicine, St. Louis, MO, USA.ORCID 0000-0001-5092-8884
Luc G T MorrisDepartment of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY, USA.ORCID 0000-0002-4417-2280
Lara DunnDepartment of Medical Oncology, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Cloud P PaweletzDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.
Dorina KallogjeriDepartment of Otolaryngology, Washington University School of Medicine, St. Louis, MO, USA.ORCID 0000-0001-5365-0988
Jay F PiccirilloDepartment of Otolaryngology, Washington University School of Medicine, St. Louis, MO, USA.
Douglas R AdkinsAlvin J. Siteman Cancer Center, Washington University School of Medicine, St. Louis, MO, USA.
Catherine J WuDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.ORCID 0000-0002-3348-5054
Ravindra UppaluriDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.ORCID 0000-0001-5988-6828
Washington University in St. Louis · USDana-Farber Cancer Institute · USBrigham and Women's Hospital · USBroad Institute · USMemorial Sloan Kettering Cancer Center · USHarvard University · USMassachusetts General Hospital · USUniversity of Pittsburgh Medical Center · US
Funding
X-RAY CRYSTALLOGRAPHYP30CA008748 · NCI · SLOAN-KETTERING INSTITUTE FOR CANCER RES · PI Nicholas D Socci · 1985 to 2026
$347.4MWashington University Center for Cellular ImagingP30CA091842 · NCI · WASHINGTON UNIVERSITY · PI TIMOTHY J. EBERLEIN · 2001 to 2026
$128.0MProject 2: Combined personal neoantigen-targeting cancer vaccines with immune checkpoint blockade for ovarian cancerP50CA240243 · NCI · DANA-FARBER CANCER INST · PI CASTRO, CESAR M, D'ANDREA, ALAN D. · 2020 to 2024
$11.5MPersonal tumor neoantigens for immunity against chronic lymphocytic leukemiaR01CA155010 · NCI · DANA-FARBER CANCER INST · PI Catherine Ju-Ying Wu · 2011 to 2026
$9.6MDefining mechanisms of immunotherapy resistance in head and neck squamous cell carcinomasU01DE029188 · NIDCR · DANA-FARBER CANCER INST · PI BARBIE, DAVID A, HADDAD, ROBERT I. · 2019 to 2019
$4.3MImmunotherapeutic responses to neoantigens in head and neck cancerR01DE027736 · NIDCR · DANA-FARBER CANCER INST · PI UPPALURI, RAVINDRA · 2018 to 2022
$2.9MNCI NIH HHS P30 CA008748NCI NIH HHS P30 CA091842NCI NIH HHS R01 CA155010NIDCR NIH HHS R01 DE027736NIDCR NIH HHS U01 DE029188
Abstract
About 50% of patients with locally advanced head and neck squamous cell carcinoma (HNSCC) experience recurrences after definitive therapy. The presurgical administration of anti-programmed cell death protein 1 (PD-1) immunotherapy results in substantial pathologic tumor responses (pTR) within the tumor microenvironment (TME). However, the mechanisms underlying the dynamics of antitumor T cells upon neoadjuvant PD-1 blockade remain unresolved, and approaches to increase pathologic responses are lacking. In a phase 2 trial (NCT02296684), we observed that 45% of patients treated with two doses of neoadjuvant pembrolizumab experienced marked pTRs (≥50%). Single-cell analysis of 17,158 CD8
Indexed as
Antineoplastic AgentsHead and Neck NeoplasmsCD8-Positive T-LymphocytesHumansNeoadjuvant TherapySquamous Cell Carcinoma of Head and NeckTumor MicroenvironmentAntineoplastic Agents
Identifiers
What OpenQuestion holds
Textmetadata
LicenceTDM
Read underepoch 390
Registered trials
NCT02296684ClinicalTrials.gov
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.